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Summary An analogue of meta-iodobenzylguanidine (MIBG) in which an aromatic hydrogen was replaced with fluorine has been found to
possess many properties similar to those of the parent compound. Moreover, 4-fluoro-3-iodobenzylguanidine (FIBG) was retained in vitro by
human neuroblastoma cells to a much greater extent than MIBG itself. Since a-emitters such as 21'At could be valuable for the treatment of
micrometastatic disease, an FIBG analogue in which the iodine atom is replaced by 21'At would be of interest. In this study, we have evaluated
the in vitro and in vivo properties of 3-[2l1At]astato-4-fluorobenzylguanidine ([2l1At]AFBG). The specific binding of [211At]AFBG to SK-N-SH
human neuroblastoma cells remained fairly constant over 2- to 3-log activity range and was similar to that of [1311]MIBG. The uptake of
[211At]AFBG by this cell line was reduced by desipramine, ouabain, 40C incubation, noradrenaline, unlabelled MIBG and FIBG, suggesting
that its uptake is specifically mediated through an active uptake-1 mechanism. Over the 16 h period studied, the amount of [2l1At]AFBG
retained was similar to that of ['311]FIBG, whereas the per cent of retained meta-[2llAt]astatobenzylguanidine ([211At]MABG) was considerably
less than that of [1311]FIBG (53% vs 75%; P < 0.05). The IC50 values for the inhibition of uptake of [1311]MIBG, [2l1At]MABG, [1251]FIBG and
[211At]AFBG by unlabelled MIBG were 209, 300, 407 and 661 nm respectively, suggesting that the affinities of these tracers for the
noradrenaline transporter in SK-N-SH cells increase in that order. Compared with [211At]MABG, higher uptake of [2l1At]AFBG was seen in vivo
in normal mouse target tissues such as heart and, to a certain extent, in adrenals. That the uptake of [211At]AFBG in these tissues was related
to the uptake-1 mechanism was demonstrated by its reduction when mice were pretreated with desipramine. However, the stability of
[21lAt]AFBG towards in vivo dehalogenation was less than that of [2llAt]MABG, as evidenced by the higher uptake of 21'At in thyroid, spleen,
lungs and stomach.
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Iodine-131-labelled meta-iodobenzylguanidine ([311I]MIBG) has
been used for the targeted radiotherapy of a number of neuro-
endocrine tumours, such as neuroblastoma (Klingebiel et al, 1989;
Garaventa et al, 1991). Although treatment ofneuroblastoma with
['311I]MIBG has been shown to be efficacious, improvements in
this therapeutic modality are needed and a number of approaches
are under active investigation. For example, combination of
[311I]MIBG treatment with high-dose chemotherapy and total body
irradiation is being pursued (Gaze et al, 1995). For micrometa-
stases, the long-range 3-particles of 'l3I are suboptimal (Sisson et
al, 1990; O'Donoghue et al, 1991) and the development of an
MIBG analogue labelled with an a-emitter such as 7.2 h half-life
21'At has been advocated (Shapiro et al, 1987; Mairs et al, 1991).
We developed amethod forthe synthesis ofmeta-[211At]astatoben-
zylguanidine ([21'At]MABG) and preliminary studies showed that
this compound behaved in a similar fashion to MIBG (Vaidyanathan
andZalutsky, 1992; Vaidyanathan et al, 1994a). Inclonogenic assays
with the SK-N-SH human neuroblastoma cell line, theDo value for
[21At]MABG was 0.2 kBq mll compared with 384 kBq ml- for no
carrier added (n.c.a.) ['311]MIBG, indicating a more than 1000-fold
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greater cytotoxicity for the cx-particle-emitting analogue over
['311]MIBG under single-cell conditions (Strickland et al, 1994).
Recently, a fluorine-containing analogue of MIBG was devel-
oped for positron emission tomography (Vaidyanathan et al, 1994b;
1995). This agent, 4-fluoro-3-iodobenzylguanidine (FIBG; Figure
1), also couldbelabelled with iodineradionuclides (Vaidyanathan et
al, 1996). The uptake and retention of FIBG in SK-N-SH human
neuroblastoma cells in vitro and mouse target tissues (heart and
adrenals) were significantly higher than those of MIBG.
Encouraged by the exquisite cytotoxicity delivered by
[2"'At]MABG, an astatinated analogue of FIBG also was synthe-
sized (Vaidyanathan et al, 1996). Herein, we have evaluated this
new agent, 3-[2l'At]astato-4-fluorobenzylguanidine ([21"At]AFBG),
with respect to its uptake and retention in SK-N-SH cells in vitro
and tissue distribution in normal mice. Like [131I]MIBG and
['311]FIBG, [2l"At]AFBG is taken up by SK-N-SH cells by an active
uptake-I mechanism. In comparison with [21'At]MABG, higher
levels of [21'At]AFBG were retained in SK-N-SH cells in vitro and
in normal, uptake-1-containing tissues (heart and adrenals) in mice.
MATERIALS AND METHODS
General
All chemicals were purchased from Aldrich Chemical Company
except as noted. Unlabelled MIBG, desipramine (DMI) and
noradrenaline (arterenol; NE) were obtained from Sigma. Sodium
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Figure 2 Paired-label dose-dependent binding of [2111]AFBG and [1311]MIBG
to SK-N-SH human neuroblastoma cells in vitro
[211At]AFBG
Figure 1 Chemical structure of [1311]MIBG, [1311]FIBG, [18F]FIBG, [211At]MABG
and [211At]AFBG
['3'I]iodide in 0.1 N sodium hydroxide was supplied by DuPont-
New England Nuclear (North Billerica, MA, USA).
Preparation of radiohalogenated benzylguanidines
Meta-iodobenzylguanidine (Vaidyanathan and Zalutsky, 1993)
and 4-fluoro-3-iodobenzylguanidine (Vaidyanathan et al, 1996)
were labelled with 1311 at the no-carrier-added level, following
procedures reported previously. Briefly, to the required amount of
['31']iodide in 1-3 pl of 0.1 N sodium hydroxide was added 10 ,l
of 0.3 M solution of N-chlorosuccinimide in trifluoroacetic acid
followed by the corresponding silicon precursor in trifluoroacetic
acid (5 ,l of0.1 M solution). After 5 min at room temperature, the
product was isolated by reversed-phase chromatography. The 2'At
activity was produced on the Duke University CS-30 cyclotron via
the 209Bi(a, 2n)2'At reaction by bombarding natural bismuth metal
targets with 28-MeV a-particles (Zalutsky et al, 1989; Larsen et
al, 1996). The activity was isolated from the target by dry distilla-
tion into either 0.1 N sodium hydroxide (0.1 ml) or chloroform
(0.5 ml). The activity trapped in 0.1 N sodium hydroxide was
concentrated to less than 3gl, or the activity trapped in chloroform
was extracted in more than 95% efficiency into 3 pl of 0.1 N
sodium hydroxide for the preparation of astatinated benzyl-
guanidines. To the activity obtained as above in a Reacti vial was
added 10 ,l of N-chlorosuccinimide and the corresponding
precursor solutions in trifluoroacetic acid, as described for the
iodination reactions. The reaction mixture was heated at 70°C for
5 min and 12 min, for [2"'At]MABG (Vaidyanathan and Zalutsky,
1992) and [2l'At]AFBG (Vaidyanathan et al, 1996) preparation
respectively, and the products were isolated by reversed-phase
chromatography.
No co-eluting mass peak was detected in the UV trace ofHPLC
analyses of any ofthese radiolabelled benzylguanidines. To date, a
maximum of at least 37 MBq of each tracer has been produced.
Since the detection limit ofiodobenzylguanidines is about 1 nmol,
the specific activities of radiohalogenated benzylguanidines is
expected to be greater than 37 TBq mmol-1. As there are no stable
isotopes of astatine, a specific activity nearer the theoretical limit
(16 000 TBq mmol-') is more likely for the astatinated agents.
Measurement of radioactivity
A dose calibrator(Capintec, CRC-7R, USA) forhigher amounts of
activity and an automated gamma counter (LKB 1282, Wallac,
Finland) for lower count rates were used. For measurement of
2"'Atactivity using the gamma-counter, the energy window was set
to encompass the Po K X-rays emitted by its electron capture
decay branch. In the dose calibrator, the window was set to that of
'33Xe. Both gamma-counter and dose calibrator had been cross-
calibrated for 2'At with a germanium semiconductor detector. For
paired-label studies, gamma-counter counting windows were set
to a dual-channel to encompass the 77-92 keV Po X-rays emitted
by '"At and the 364-keV gamma-rays of "3'I. Counting data were
automatically corrected for the 11% crossover of 1311 in the 2"'At
gate and the physical decay ofboth nuclides.
Cells and culture conditions
The human neuroblastoma cell lines SK-N-SH (uptake-1 positive)
and SK-N-MC (uptake-I negative) (Biedler et al, 1973) were
purchased from American Type Culture Collection (Rockville,
MD, USA). The incubation medium (JRH Biosciences, Lenexa,
KS, USA) was made by mixing 440 ml of RPMI-1640, 50 ml of
Serum Plus, 5 ml of penicillin-G/streptomycin (5000 U of peni-
cillin and 5000 ,tg of streptomycin in 1 ml) and 5 ml ofglutamine
(200 mm in saline). The cells were grown at 37°C in a humidified
incubator containing 5% carbon dioxide. Cell viability was
evaluated before each binding experiment by trypan blue dye
and was 95-98% for all studies.
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Figure 3 Effect of various agents and conditions on the uptake of
[21'At]AFBG by SK-N-SH human neuroblastoma cells
Paired-label in vitro binding of [21'At]AFBG and
[1311]MIBG to SK-N-SH human neuroblastoma cells
The cells were seeded into 24-well plates (4 x 105 cells in 500 ,l
medium per well) and incubated for 24 h in a 37°C/5% carbon
dioxide humidified atmosphere. After removing the medium,
fresh medium containing 0.26-50.32 kBq of [11]MIBG and
[21 At]AFBG was added and the cells were incubated for 2 h at
370C. The medium was removed at the end of incubation and the
cells were washed twice with phosphate-buffered saline. The cells
were solubilized by incubation with 500 ,l of 0.5 N sodium
hydroxide for 30 min at room temperature and then removed with
cotton swabs. The cell-bound activity was counted along with
input standards using a dual-channel gamma-counter. Each
measurement was performed in quadruplicate. In all cases, non-
specific binding was determined by preincubating cells with DMI
(50 FtM) for 30 min before adding the tracers, or using the uptake- 1
negative cell line SK-N-MC.
Specificity of [211At]AFBG uptake in SK-N-SH cells
The cells were seeded into 24-well plates (4 x 105 cells in 500 ,l of
medium per well) and incubated for 24 h. To determine the effect
of DMI and ouabain, after removing medium the cells were pre-
incubated with 500gl ofmedium containing 1.5 gM DMI or 1 mM
ouabain for 30 min at 37°C. After this period, the medium was
aspirated and fresh medium containing 2.8 kBq of [211At]AFBG
was added. Cells were then incubated for 2 h at 37°C. To deter-
mine the effect of temperature, cells were plated as above. After
24 h, medium was removed, 450 gl of fresh medium was added
and incubated at 40C for at least 1 h. Subsequently, 2.8 kBq of
[211At]AFBG was added followed by incubation for 2 h at 4°C.
Blocking effects of NE (50 JIM), MIBG (10 JIM) and FIBG
(10 JM) were determined by co-incubating the cells with the
tracers and these agents for 2 h at 37°C. In all experiments, the
cell-associated activity was determined as described above. The
per cent binding to the cells was normalized to incubations
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Figure 4 Retention of benzylguanidines by SK-N-SH cells after removal of
unbound activity in the presence and absence of DMI. (A) [1311]FIBG and
I21"At]AFBG., (3), [2l'At]AFBG; [!, [2l"At]AFBG+DMI; *, [1311]FIBG; *,
[1311]FIBG+DMI. (B) [131]FIBG and [2l1At]MABG, *, [2l1At]MABG; *,
I21"At]MABG+DMI; A ['3'1]FIBG; [g, [1311]FIBG+DMI
performed simultaneously without interventional agents. Each
measurement was performed in quadruplicate.
Paired-label retention of [211At]AFBG and [131I]FIBG, and
[131I]FIBG and [21'At]MABG, in SK-N-SH cells
Cells were loaded onto 24-well plates at a density of 5 x 105 cells
per well per 500gl ofmedium and incubated at 370C for 24 h. After
the 24-h period, the medium was replaced with fresh medium
containing 5.6 kBq of each tracer in a total volume of 500 JIl per
well. The cells were incubated with the activity for 2 h at 37°C. At
the end of this incubation period, the medium was removed and
supplemented with 500 ,ul offresh medium with and without 1.5 JM
DMI. The cell-bound activity was determined at 0, 2, 4, 6, 16 and
24 h after the initial uptake. Each time point was done in quadru-
plicate. The activity retained at each time point was normalized to
the initially bound activity to calculate the per cent retained activity.
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Figure 5 Effect of graded concentrations of unlabelled MIBG on the uptake
of [1311]MIBG, [1251]FIBG, [211At]MABG and [2l1At]AFBG by SK-N-SH cells. 0,
[1311]MIBG; C~,I21'At]MABG;o, [1251]FIBG; A, I21"At]AFBG
Effect of graded concentrations of unlabelled MIBG on
the uptake of [1311]MIBG, [1251]FIBG, [211At]MABG and
I211At]AFBG by SK-N-SH cells
Cells (4 x 105) were incubated in quadruplicate with 3.7 kBq of
each tracer in the absence and presence of various concentrations
(10 pM to 10 gM) of unlabelled MIBG at 37°C for 2 h and the
percentage cell-bound activity was determined as above. The
specific binding at each concentration of MIBG was obtained by
subtracting the binding observed at 10gM MIBG from the binding
at each concentration. These values were normalized to the
maximum binding and plotted against the MIBG concentrations.
Biodistribution in normal mice
Several experiments were performed. Male BALB/c mice
weighing about 25 g were used for all experiments. Groups offive
mice were used for each time point. The tracers were injected via
the tail vein. The mice were killedby an overdose ofhalothane and
tissues of interest were isolated, washed, blot-dried and counted
for '3'I and 21 At using a dual-label programme in a gamma-
counter. A 5% or 10% aliquot of the injected activity was also
counted so that the percentage of injected dose per organ or per
gram oftissue could be computed.
Tissue uptake of [21'At]AFBG was compared with that of
['3'1I]MIBG at 1 h and 4 h afterinjection and with that of['311I]FIBG
at 1 h, 4 h and 24 h by administering 185-370 kBq ofeach tracer.
'The tissue distribution of [2"'At]MABG and [21'At]AFBG at 1 h,
4 h and 24 h was also determined in parallel experiments. The
specificity ofuptake was determined by investigating the effect of
desipramine on the uptake of [21"At]AFBG in the heart and
adrenals, tissues that have an active uptake-I mechanism. In these
experiments mice were pretreated with a PBS solution of
desipramine (10 mg kg-') i.p. 30 min before administering the
tracers. The control group received just the saline vehicle and the
tracer. The tissue uptake was determined at 1 h after injection of
the radioactivity. Statistical significance of differences was deter-
mined by paired or independent Student t-tests. The differences
were considered to be significant ifP-values were less than 0.05.
RESULTS
Radioactivity-dependent binding of [1311]MIBG and
[211At]AFBG to SK-N-SH cells
The specific binding of['3II]MIBG and [21'At]AFBG by SK-N-SH
cells as a function of activity concentration is shown in Figure 2.
The binding of[2I1At]AFBG was reasonably constant (40-61%) in
the activity range studied, and was virtually identical to that ofno-
carrier-added ['3'I]MIBG at each activity level. The non-specific
binding, determined by pretreatment of SK-N-SH cells with DMI
and/or by using SK-N-MC line, was less than 2% in all cases.
Specificity of uptake by SK-N-SH cells
The uptake of [2l1At]AFBG was blocked, to varying degrees, by
several interventional agents and incubation at 40C (Figure 3). At a
concentration of 1.5 gM, the uptake-I inhibitor DMI reduced the
uptake of [211At]AFBG to 17% of the control values. Whereas
ouabain (1 mM) reduced the uptake to 37% of control values, incu-
bation at 4'C reduced it to 11%. These data suggest that the uptake
process is energy dependent. The specificity of uptake is further
demonstratedbyits inhibitionby 50gM noradrenaline, 10gM MIBG
and 10gM FIBG to 9%, 7% and 6%, respectively, ofcontrol values.
Retention of [2l1At]AFBG and [21'At]MABG by SK-N-SH
cells
The ability of SK-N-SH cells to retain [211At]AFBG and
[2"1At]MABG in comparison with that of [131I]FIBG is shown in
Figure 4A and B. Over the 16-h period studied, the amount of
[2l1At]AFBG retained was similar to that of [13'I]FIBG. In contrast,
by 16 h, the amount ofinitially bound [2l'At]MABG was consider-
ably less than that of ['31I]FIBG (53% vs 75%; P < 0.05). The
difference was even more apparent at 24 h (42% vs 73%; P < 0.05).
Treatment with DMI diminished the capacity of the cells to retain
[211At]AFBG and [2l1At]MABG, suggesting that reuptake of these
tracers in SK-N-SH cells occurs as is seen with MIBG.
lC.0 of MIBG for blocking the uptake of [1311]MIBG,
[1251]FIBG, [211At]MABG and [2'1At]AFBG by SK-N-SH
cells
Figure 5 shows the inhibition of uptake of various benzylguani-
dines by graded concentrations of unlabelled MIBG. The pattern
of the curves is similar for all four benzylguanidines. The IC50
values were 209, 300, 407 and 661 nm respectively for ['311]MIBG,
[2l'At]MABG, ['251]FIBG and [2l"At]AFBG, suggesting that the
affinities for these tracers to the noradrenaline transporter in
SK-N-SH cells increase in that order.
Biodistribution studies
Tables 1 and 2 show the data from biodistributions of [2l"At]AFBG
in comparison with that of ['311]MIBG and ['311]FIBG. At 1 h, the
heart uptake of [2"1At]AFBG (22.4 ± 2.1% ID/g) was not different
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Table 1 Paired-label tissue distribution of [211At]AFBG and [13l1]MIBG in BALB/c mice
Per cent injected dose per gram of tissuea
Tissue 1 h 4 h
[21'At]AFBG ['311]MIBG [2l"At]AFBG I1311]MIBG
Liver 6.1 ± 1.0 8.5± 0.7 2.6 ± 0.3 4.5+ 0.6
Spleen 7.0 ± 0.7 4.6 ± 0.8 5.3 ± 0.7 3.5 ± 0.5
Lungs 14.4 ± 4.7 9.3 ± 2.9 5.6 ± 1.3 3.9 ± 0.7
Heart 22.4±2.1 22.7±3.0b 18.4±2.2 14.8±1.6
Kidney 4.2 ± 0.4 3.0 ± 0.4 3.1 ± 0.3 1.9 ± 0.2
Stomach 12.0 ± 4.8 4.8 ± 1.8 11.4 ± 1.7 2.0+ 0.3
Small intestine 4.9 ± 0.6 8.2 ± 0.9 2.3 + 0.5 3.8 ± 0.7
Large intestine 3.1 ± 0.4 3.8 ± 0.6 2.0 ± 0.2 4.6 + 0.6
Thyroidc 0.7±0.1 0.5±0.1 1.6±0.5 0.5±0.3
Muscle 2.3 ± 0.3 2.1 ± 0.3 1.3 ± 0.2 1.2 ± 0.2
Bone 1.4 ± 0.2 1.1 ± 0.2 1.0 ± 0.2 0.8± 0.2
Blood 1.5±0.1 0.9±0.1 0.9±0.1 0.4±0.0
Brain 0.2 ± 0.0 0.1 ± 0.0 0.2± 0.1 0.1 ± 0.1
Adrenals 18.8±1.6 19.1 ±2.5b 22.0±8.4 26.2±9.7
aMean ± s.d.; five animals per time point. bDifferences not statistically significant (P> 0.05) by paired t-test. cPer cent
injected dose per organ.
Table 2 Paired-label tissue distribution of [211At]AFBG and [1311]FIBG in BALB/c mice
Per cent injected dose per gram of tissuea
Tissue 1 h 4 h 24 h
I211At]AFBG ['311]FIBG [21lAt]AFBG [1311]FIBG [21At]AFBG ['311]FIBG
Liver 4.7± 1.1 7.9 ± 1.2 2.7± 0.2 7.2 ± 0.3 0.7± 0.1 1.9± 0.2
Spleen 5.9 ± 0.5 4.0 ± 0.2 5.1 ± 0.4 3.1 ± 0.3 2.6± 0.6 3.5 ± 0.7
Lungs 9.9 ± 1.8 9.0 ± 1.2 5.4 ± 1.0 4.8± 0.4b 2.2 ± 0.6 1.8± 0.4b
Heart 22.1 ± 4.9 21.4 ± 5.2 17.4 ± 1.6 18.1 ± 2.0 7.8± 1.6 10.9 ± 2.0
Kidney 3.3 ± 0.3 2.6 ± 0.3 2.7 + 0.3 2.0 ± 0.2 1.3 ± 0.2 1.2 ± 0.2b
Stomach 6.4 ± 2.0 2.2 ± 1.0 11.3 ± 3.8 2.6 ± 1.3 6.5 ± 1.3 1.3± 0.2
Small intestine 3.1 ± 0.8 4.8 ± 1.3 2.9 ± 0.2 4.0 ± 0.3 1.3 ± 0.2 2.1 ± 0.0
Large intestine 2.6 ± 0.5 3.2 ± 0.7 2.6 ± 0.4 4.1 ± 0.5 1.0 ± 0.1 2.0 ± 0.2
Thyroidc 0.8±0.3 0.6±0.2 1.7±1.0 0.7±0.5 1.0±0.2 0.3±0.1
Muscle 2.1 ±0.2 1.7±0.2 1.8±0.2 1.4±0.2 0.5±0.1 0.7±0.1
Bone 1.3±0.2 0.9±0.1 1.3±0.1 0.8±0.1 0.3±0.1 0.2±0.Ob
Blood 1.4 ±0.1 0.9 ±0.0 1.1 ±0.1 0.5±0.1 0.3±0.1 0.1 ±0.0
Brain 0.3 + 0.1 0.2 ± 0.1 0.5 ± 0.3 0.3 + 0.4 0.1 + 0.0 0.1 ±0.1b
Adrenals 16.0 ± 3.0 15.3 ± 3.1b 14.8 ± 3.8 13.2 ± 2.1b 8.6 ± 1.5 12.5 ± 0.9
aMean ± s.d. (n = 5). bDifferences not statistically significant (P> 0.05) by a paired t-test. cPer cent injected dose per organ.
(P > 0.05) from that of ['3'I]MIBG (22.7 ± 3.0% ID/g). However, at
4 h, the heart uptake of [211At]AFBG (18.4 ± 2.2% ID/g) was about
25% higher (P < 0.05) than that of ['311]MIBG (14.8 ± 1.6% ID/g).
At 1 h and 4 h, the heart uptake of [2I1At]AFBG (22.1 ± 4.9% ID/g
and 17.4 ± 1.6% ID/g respectively) and [1311]FIBG (21.4 ± 5.2 and
18.1 ± 2.0% ID/g respectively) was similar; at 24 h, the heart uptake
of['31I]FIBG (10.9±2.0% ID/g) was significantly higherthanthatof
[2l1At]AFBG (7.8 ± 1.6% ID/g). The adrenal uptake of[2l1At]AFBG,
while similar at early time points to that of the iodinated benzyl-
guanidines, was significantly lower at later time points. The speci-
ficity of uptake of [21'At]AFBG in vivo was demonstrated by its
inhibition with DMI. One hour after the tracer injection, DMI
pretreatment reduced the heart and adrenal uptake of [211At]AFBG
to 68% and 71% of the control values respectively (P < 0.05).
Compared with [1311]MIBG, spleen, lungs and stomach showed
significantly higheruptake of[2l"At]AFBG. Lung and spleen uptake
of [2l'At]AFBG was similar to that of [31I]FIBG; however, stomach
uptake of [21lAt]AFBG was three- to fivefold higher than that of
['311]FIBG. Thyroid uptake of [2l1At]AFBG was two- to threefold
higher than that of ['311]MIBG and ['31I]FIBG. Liver and intestines
retained [211At]AFBG to a lower degree than ['311]MIBG and
[1311]FIBG. As shown in Table 3, results from parallel experiments
showed that spleen, lung, thyroid and stomach uptake of
[211At]AFBG was consistently higher than that of [211At]MABG,
suggesting that the lesser stability ofthe formertowards dehalogena-
tion in vivo.
DISCUSSION
An important factor in the optimization of endoradiotherapy is to
match the properties ofthe emitted radiation with the characteristics
of the tumour target. For micrometastatic disease, the radionuclide
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Table 3 Tissue distribution of [2"At]AFBG and [211At]MABG in BALB/c mice
Per cent injected dose per gram of tissuea
Tissue 1 h 4 h 24 h
[211At]AFBG [21At]MABG [21At]AFBG [21At]MABG [21At]AFBG [21At]MABG
Liver 6.2 + 1.0 10.6 ± 1.2 3.3 + 0.5 5.2+ 0.7 1.0 + 0.2 1.5 + 0.2
Spleen 7.0 + 1.0 5.5 ± 0.1 6.2 ± 0.7 4.9 + 0.3 2.8 + 0.3 3.4 ± 0.5
Lungs 14.5 ± 3.2 10.7 ± 1.4 6.7 + 1.8 5.2±O.9b 2.5 + 0.4 2.2+ 0.4b
Heart 22.6 + 1.6 26.7+ 1.4 19.5 + 2.7 17.1 + 1.3b 9.7 ± 0.8 7.3 + 0.6
Kidney 3.8 ± 0.4 3.6+ 0.3b 3.5 + 1.0 2.4+ 0.1 1.5 + 0.2 1.5+ 0.3b
Stomach 11.6 +4.2 5.7+ 1.3b 13.3 ± 4.1 5.4 ± 0.7 4.4 + 1.4 3.7+ 0.8b
Small intestine 4.7 ± 0.8 7.5 ± 0.8 3.2 + 0.5 5.4 + 0.8 1.2 ± 0.2 2.8 + 0.5
Large intestine 3.0 ± 0.6 3.6 ± 0.5b 2.4 + 0.4 5.1 + 0.6 0.9 + 0.1 2.2 ± 0.3
Thyroidc 0.6±0.1 0.4±0.1 1.4+0.5 0.5+0.2 0.5+0.1 0.3±0.1b
Muscle 2.6+0.4 3.0+0.2b 1.7±0.2 1.9±0.1 0.6+0.1 0.8+0.1
Bone 1.7+0.4 1.5+0.2b 1.6±0.0 1.2+0.4b 0.2+0.1 0.4+0.1
Blood 1.3±0.1 0.9±0.1 0.9+0.2 0.4+0.1 0.2+0.0 0.2+0.1b
Brain 0.2 + 0.0 0.2 + 0.0 0.2 ± 0.0 0.1 ± 0.1 0.1 +.0 0 .+Q± O.Ob
Adrenals 13.6 + 0.9d 21.6 + 0.7 13.4 ± 2.3 12.3 + 3Q0b 11.4 + 4.0 15.0 ± 2.6b
aMean ± s.d. (n = 5). bDifferences not statistically significant (P > 0.05) by a Student t-test. cPer cent injected dose per organ. dn = 4.
2"At is particularly appealing since its a-particles deposit their
energy over a range equivalent to only a few cell diameters. In addi-
tion, these a-particles are radiations of high linear energy transfer
with a relative biological effectiveness higher than p-particles, such
as those emitted during the decay of '3'I. This has led a number of
investigators to suggest that a 2"'At-labelled analogue of['311]MIBG
might be a more effective agent for the treatment ofneuroblastoma
(Shapiro and Gross, 1987; Kemshead et al, 1990; Mairs et al, 1991).
Indeed, recent in vitroexperiments have confirmed thatunder single
cell conditions, thecytotoxicity of[2I1At]MABG was three orders of
magnitude higher than that of [311I]MIBG (Strickland et al, 1994).
The results obtained in vitro with [211At]MABG have been
highly encouraging; however, other2"'At-labelled MIBG analogues
may have even more favourable properties as endoradiotherapeutic
agents. While rapid uptake of [211At]MABG in human neuro-
blastoma cell lines was achieved, rapid washout was also
observed, particularly in the SK-N-SH line, in which a retention
half-life of 5-6 h was seen (Strickland et al, 1994). Recently, we
have reported that substitution ofa fluorine atomortho to the iodine
in MIBG resulted in an MIBG analogue, ['311]FIBG, with modestly
increased binding, but significantly enhanced retention of radio-
iodine in SK-N-SH cells in vitro (Vaidyanathan et al, 1997). Given
the similar behaviour of [211At]MABG and ['31I]MIBG, we
performed the current study to determine whether fluorine substitu-
tion ortho to the astatine atom in [211At]MABG would have a
similar effect.
As a paired-label comparison of [211At]MABG and
[2 'At]AFBG would not be possible because of the lack of appro-
priate astatine radionuclide for use in tandem with 2I'At, two sepa-
rate comparisons were performed. The first demonstrated that the
uptake and retention of[211At]AFBG by SK-N-SH cells was essen-
tially identical to that of ['311]FIBG over 16 h, an experimental
period over which the 21'At had decayed to about 21% of initial
levels. In the second paired-label experiment, the binding of
[211At]MABG was compared directly with that of ['311]FIBG.
Unlike the results of the previous experiment, the maximal uptake
of 21'At activity was significantly lower than that of '3'I. In addi-
tion, the retention of [21'At]MABG by this neuroblastoma cell line
was lower than that of ['311]FIBG, with the difference increasing
with time. These results suggest that the radiotoxicity of
[211At]AFBG for SK-N-SH cells should be even greater than that
of [211At]MABG and experiments are planned to confirm this
speculation.
If [21'At]AFBG is to be pursued as an endoradiotherapeutic
agent, it is critical to understand the mechanisms responsible for
its uptake not only in human tumour cells, but also in normal
tissues such as heart and adrenals, where uptake-1-mediated local-
ization could be problematical. In SK-N-SH cells, MIBG is taken
up by a neuron-specific active uptake-I mechanism (Buck et al,
1985; Smets et al, 1989), a process that has been demonstrated to
occur with the analogues [21'At]MABG (Vaidyanathan and
Zalutsky, 1994a), ['8F]FIBG (Vaidyanathan et al, 1994b, 1995)
and ['311]FIBG Vaidyanathan et al, 1997).
The results ofthis study suggest that the uptake-I mechanism is
also responsible for the accumulation of[211At]AFBG in SK-N-SH
neuroblastoma cells. The tricyclic antidepressant DMI, norepin-
ephrine, MIBG and FIBG all were effective in blocking uptake of
[211At]AFBG to a similar degree as observed for ['3111251]MIBG,
[211At]MABG and ['8F/1'311]FIBG. In addition, [211At]AFBG accu-
mulation is energy dependent as performing the incubation at 4°C,
or in the presence ofouabain, resulted in a marked decrease in cell
binding. Finally, uptake of [2'At]AFBG was reduced significantly
in the heart and adrenals of mice pretreated with the uptake-1
inhibitor DMI, albeit to a slightly lesser degree than that
reported for MIBG and other halobenzylguanidine analogues
(Vaidyanathan et al, 1995; 1997; Valette et al, 1993). Taken
together, these results suggest that substitution of astatine for
iodine in the FIBG molecule does not interfere with the uptake-1
mechanism responsible for the accumulation of halobenzyl-
guanidines in this human neuroblastoma cell line.
Differences in the mechanism of tracer uptake between
[211At]AFBG and [211At]MABG thus do not explain the higher
uptake and retention of the former in the SK-N-SH cell line. One
possibility is that the presence of the fluorine atom enhances the
inertness of [21 At]AFBG to catabolic breakdown, as fluorine
substitution has been a general tactic to increase the metabolic
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stability of a variety of pharmaceuticals (Barnette, 1984). With
regard to our particular application, as fluorine is the most electro-
negative element, its presence could stabilize weaker adjacent
carbon-halogen bonds (Goldman, 1969). However, as discussed
later, this is contradicted by the fact that deastatination of
[211At]AFBG appears to occur more readily than [21'At]MABG.
Substitution of fluorine for hydrogen in MIBG has been shown
to increase slightly lipophilicity (Vaidyanathan et al, 1994b) and as
a result, could partially account for the increased binding and
retention of FIBG by SK-N-SH cells. If lipophilicity were the
predominating factor, then one would expect [21'At]AFBG to
exhibit even higher binding because of the greater lipophilicity
of astatine compared with iodine (Vaidyanathan et al, 1994b);
however, our results indicate nearly identical in vitro behaviour of
[2'At]AFBG and [1311]FIBG. Other possible effects of fluoro
substitution on the cellular retention of halobenzylguanidine
analogues, include alterations in the affinity forthe norepinephrine
transporter working in the reverse mode (Servidei et al, 1995) or
changes in the intracellular storage site. The affinity of four
halobenzylguanidines for the uptake transporter is indeed
different, as shown by the IC5 values ofMIBG fortheir inhibition.
Decreasing the loss oflabel from an endoradiotherapeutic agent
is important not only for maximizing radiation absorbed dose to
tumour, but also for minimizing deleterious effects to normal
tissues. MIBG is considered to be metabolically stable (Mangner
et al, 1986); however, paired-label studies in normal mice have
demonstrated that thyroid uptake of radioiodine following
administration of ['311]FIBG was 2-3 times lower than that from
['251]MIBG, suggesting an enhanced inertness to deiodination for
the former (Vaidyanathan et al, 1997). Based on these results, we
anticipated that substitution ofa fluorine atom ortho to the astatine
would decrease the rate ofdeastatination as well.
The relative selectivity of astatide for spleen and lungs is about
ten times higher than that for iodide (Garg et al, 1990), so accumu-
lation of activity in these tissues following paired injection of
21At- and '311-labelled analogues is consistent with deastatination
in vivo. When the tissue distribution of [211At]AFBG and
['311]FIBG was compared, uptake of both radionuclides in the
lungs was quite similar and no consistent trend was observed with
regard to 211At/'311 spleen uptake ratios. However, the accumula-
tion of [21 At]AFBG in the spleen, lungs, thyroid and, barring a
few, in most other tissues was higher than that seen for
[21'At]MABG. This could reflect a general effect of fluorine
substitution, analogous to the increased tissue retention of FIBG
compared with MIBG (Vaidyanathan et al, 1997), or a greater
susceptibility of[21'At]AFBG to deastatination. Although the latter
is a distinct possibility, it is difficult to explain why ortho substitu-
tion of a fluorine for a hydrogen could decrease the rate of
deiodination but increase the rate of deastatination. Labelled
catabolite analyses will be performed in order to investigate
further the nature ofthese differences.
In summary, the results ofthis study demonstrate that the uptake
characteristics of [211At]AFBG in the SK-N-SH human neuro-
blastoma line are mediated by an active uptake-I mechanism and,
like other no-carrier-added halobenzylguanidine preparations, is
not saturable over a 2-log activity range. Compared with
[21'At]MABG, [21'At]AFBG offers the advantage of higher reten-
tion in neuroblastoma cells in vitro, but the disadvantage ofhigher
retention in normal tissues in vivo. Preliminary results of studies
performed in an athymic mouse human neuroblastoma xenograft
model, to be published elsewhere, indicate tumour-to-normal
tissue ratios for [21'At]AFBG in heart, adrenals and liver that are
higher than those observed with [I'tAt]MABG.
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